Adipotide1kits (10Vials)

Adipotide (FTPP) – Detailed Introduction & Benefits Adipotide (also known as FTPP – Fat-Targeted Proapoptotic Peptide , Prohibitin-TP01) is a synthetic chimeric peptidomimetic (~2.5 kDa) designed for targeted fat reduction. Sequence : CKGGRAKDC-GG-D(KLAKLAK)₂ Structure : Two domains linked by a short spacer: Targeting domain (CKGGRAKDC) : Binds prohibitin (a protein overexpressed on white adipose tissue (WAT) blood vessels ). Pro-apoptotic domain (D(KLAKLAK)₂) : D-amino acid sequence, protease-resistant, triggers cell death. Classification : Experimental anti-obesity / adipose vasculature-targeting peptide . Status : Preclinical + Phase 1 trials (discontinued in 2012 due to renal safety signals; not FDA/EMA approved ). 2. Mechanism of Action (How It Works) Unlike appetite suppressants or metabolism boosters, Adipotide acts as a “fat vessel missile” : Homing : The CKGGRAKDC domain binds prohibitin on endothelial cells lining white fat blood vessels . Internalization : The peptide enters the cell via endocytosis. Apoptosis : The (KLAKLAK)₂ domain disrupts mitochondrial membranes → endothelial cell death . Fat necrosis : Loss of blood supply → adipocyte starvation & death → body clears dead fat tissue. Key selectivity : Spares brown fat, muscle, and most organs; targets only white adipose vasculature . 3. Proven Benefits (Preclinical & Primate Data) ① Rapid, Targeted Fat Loss In obese rhesus monkeys: 11% body weight loss in 28 days ; 39% reduction in fat mass (MRI/DEXA confirmed). Primarily reduces visceral fat (abdominal fat linked to diabetes & heart disease). Works in diet-induced & genetic obesity models (rodents + primates). ② Improves Insulin Sensitivity & Metabolic Health Sharply lowers insulin resistance (reduced insulin AUC in monkeys). Benefits prediabetes, Type 2 diabetes , and metabolic syndrome. No ectopic fat buildup in liver or arteries (studied up to 28 days). ③ Non-Stimulant, Peripheral Action No CNS stimulation → no jitters, anxiety, or insomnia . Does not disrupt hunger hormones (leptin, ghrelin) long-term. ④ Reduces Obesity-Related Risks Lowers risk of cardiovascular disease , fatty liver, and PCOS via fat mass reduction. 4. Administration & Dosing (Research Use Only) Route : Subcutaneous injection (most common); IV in trials. Typical dose : 0.1–0.43 mg/kg daily . Cycle : 4–6 weeks (with breaks to avoid vascular regeneration). Onset : Visible fat loss in 1–2 weeks ; peak effects at 4 weeks . 5. Safety Profile (Critical Notes) Common (Mild, Reversible) Mild creatinine elevation (kidney stress signal). Electrolyte shifts (easily corrected). Injection site redness/swelling. Key Risk (Led to Trial Discontinuation) Dose-dependent renal proximal tubule changes (reversible in primates at optimal doses). Contraindications : Pregnancy, lactation, dehydration, nephrotoxic meds, kidney disease. 6. Summary Adipotide (FTPP) is a first-in-class targeted fat-killing peptide that eliminates white fat by destroying its blood supply. In primates, it delivers rapid visceral fat loss and dramatic insulin sensitivity improvements without CNS side effects. Though promising, it remains experimental due to renal safety concerns , and is for research purposes only (not for human medical use).